Io Therapeutics, Inc., Announces Presentation of Data on Its RAR Gamma Agonist Compound IRX5010 Demonstrating Inhibition of Tumor Infiltrating Myeloid Derived Suppressor Cells, Promotion of Tumor Infiltrating T-Cells, and Effective Tumor Growth Inhibition in Murine Models of Breast, Colorectal, and Prostate Cancers

Io Therapeutics, Inc., presented results from studies done in breast, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear receptor gamma, which was discovered in the company’s oncology drug program.